Missing immune response may prove a vital link for new leukaemia treatments

September 20, 2013

(Medical Xpress)—Patients suffering from leukaemia could have their immune system engineered to fight the disease, after scientists at the University of Birmingham discovered that they lacked an immune response to a certain class of proteins which could be restored through stem cell transplants.

The discovery may even eventually lead to a vaccination against leukaemia for at risk groups who are found to be lacking the necessary immune response – meaning that individuals may then rely on their to kill before the disease takes hold.

Cell growth and survival are controlled by complex signalling pathways, but in these signals have gone awry. The signals are transmitted using protein modifications, such as adding a phosphate group. This modification is retained when the proteins are broken up into fragments, called , and presented on the for inspection by (T cells). This results in the presentation of phosphopeptides by leukaemia cells, enabling them to be recognised as abnormal by the immune system.

The Birmingham researchers identified 95 phosphopeptides from leukaemia samples, taken directly from patients.

They went on to show that healthy people exhibited an unexpected immune response, with T-cells that recognised these phosphopeptides, and that this response was lacking in patients with leukaemia.

When leukaemia sufferers were given a , there was a dramatic recovery of this response andT-cells recognising phosphopeptides-were able to kill leukaemia cells in the lab.

The researchers concluded that phosphopeptides may therefore be the target of cancer in humans – giving rise to the possibility of new treatments, which include engineering T-cells outside of the body to equip them with the immune response needed to fight the leukaemia, before putting them back into the patient.

The discovery also gives rise to the possibility of screening people to see if they have the immune response – those who do not may be at risk of developing leukaemia, and a vaccination could even be developed to protect these people with the necessary .

Dr Mark Cobbold, from the School of Immunity and Infection at the University of Birmingham, said: "This is the first study to identify phosphorylated tumour antigens that are present on patient tumour samples and also the first study to look at immune responses to this new group of antigens in humans.

"We were surprised to see that healthy individuals had immunity to these antigens. It could be that just as our immune system fights off infections on a daily basis, it is also fighting cells that develop mutations that could lead to cancer.

"As we enter old age these responses could wane and this would explain why, just as older people get more serious infections due to impaired immunity, older people are also at greater risk from cancer.

"These findings need to be confirmed by other research groups, but could lead to new treatment options for patients with leukaemia or other cancers or preventative vaccination for at-risk groups."

Professor Chris Bunce, Research Directorat Leukaemia & Lymphoma Research, which part funded the study, said: "Stemcell transplants can offer leukaemia patients the chance of a complete cure but they are not always successful and can have severe side-effects. By pinpointing key antigens, some of which are found only on the surface of leukaemia cells, this research could lead to new ways of modifying patients' own immune systems to attack only leukaemia cells or even stop them from developing in the first place."

The research MHC Class I-AssociatedPhosphopeptides Are the Targets of Memory-like Immunity in Leukemia is published online in Science Translational Medicine today. Thework was funded by Leukaemia & Lymphoma Research and the Kay Kendal LeukaemiaFund.

Explore further: Origin of chronic lymphatic leukaemia: lead discovered

Related Stories

Origin of chronic lymphatic leukaemia: lead discovered

April 11, 2012
Up until now the causes of the development of chronic lymphatic leukaemia, the most common form of cancer of the blood in Europe, have been unknown. At present a cure is not possible. A research group at the MedUni Vienna ...

Scientists harness immune system to prevent lymphoma relapse

October 18, 2012
UK scientists hope that lymphoma patients could benefit from a new drug that triggers the cancer-fighting properties of the body's own immune system, after highly promising early laboratory results.

Rare leukaemia survival-rate breakthrough

August 13, 2013
A pioneering genetic study means that children with a rare subtype of leukaemia have 75% less chance of their leukaemia recurring.

Nuclear power plants do not raise risk of leukaemia in children

September 13, 2013
Young children who live near nuclear power plants do not have a greater risk of developing childhood leukaemia or non-Hodgkin Lymphoma according to research published in the British Journal of Cancer today (Friday).

Boosting immune responses against leukaemia

November 21, 2012
(Medical Xpress)—In the first of its kind, a translational study undertaken at the Malaghan Institute of Medical Research has revealed that boosting the activity of a rare type of immune cell could be an effective way to ...

Scientists seek out cancer cells hiding from treatment

January 15, 2013
Scientists hope to improve leukaemia treatment by investigating how cancer cells use 'hiding places' in the body to avoid chemotherapy drugs.

Recommended for you

Immune cells may be key to better allergy, infection therapies

July 28, 2017
By learning how a recently discovered immune cell works in the body, researchers hope to one day harness the cells to better treat allergies and infections, according to new Cornell research.

Team finds link between backup immune defense, mutation seen in Crohn's disease

July 27, 2017
Genes that regulate a cellular recycling system called autophagy are commonly mutated in Crohn's disease patients, though the link between biological housekeeping and inflammatory bowel disease remained a mystery. Now, researchers ...

Co-infection with two common gut pathogens worsens malnutrition in mice

July 27, 2017
Two gut pathogens commonly found in malnourished children combine to worsen malnutrition and impair growth in laboratory mice, according to new research published in PLOS Pathogens.

Study sheds light on how body may detect early signs of cancer

July 26, 2017
Fresh insights into how cells detect damage to their DNA - a hallmark of cancer - could help explain how the body keeps disease in check.

How genetically engineered viruses develop into effective vaccines

July 26, 2017
Lentiviral vectors are virus particles that can be used as a vaccine to stimulate the immune system to fight against specific pathogens. The vectors are derived from HIV, rendered non-pathogenic, and then engineered to carry ...

Accounting for human immune diversity increases clinical relevance of fundamental immunological research

July 26, 2017
Mouse models have advanced our understanding of immune function and disease in many ways but they have failed to account for the natural diversity in human immune responses. As a result, insights gained in the lab may be ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.